1. A method for treatment of neurodegenerative disease, comprising administering to an individual in need of such treatment a therapeutically effective amount of a compound having structure:wherein R is hydrogen, or a C1 to C10 alkyl, C2 to C10 alkynyl, or C2 to C10 alkoxyalkyl group, optionally including heteroatoms;Y1 and Y2 are independently C or N;
X4 is hydrogen or halogen;
X3 is CH2, CF2, S, SO, SO2, O, NH, or NR2, wherein R2 is alkyl; and
X2 is halogen, alkyl, halogenated alkyl, alkoxy, halogenated alkoxy, hydroxyalkyl, pyrollyl, optionally substituted aryloxy, alkylamino, dialkylamino, carbamyl, amido, alkylamido, dialkylamido, acylamino, alkylsulfonylamido, trihalomethoxy, trihalocarbon, thioalkyl, SO2-alkyl, COO-alkylm NH2, OH, or CN; and
X1 has the formula XYZ wherein, X, Y and Z are independently C, N, S or O, connected by single or double bonds and with apporpriate hydrogen substitution to satisfy valence, or Y may be (CH2)2,wherein one of X and Z is bonded at the 5?-position to the aryl ring and the other is bonded to the 4?position, and wherein the compound is optionally in the form of an acid addition salt;wherein the neurodegenerative disease is selected from the group consisting of complete androgen insensitivity syndrome (CAIS), spinal and bulbar muscular atrophy (SBMA or Kennedy's disease), Alzheimer's Disease (AD), sporadic frontotemporal dementia with parkinsonism (FTDP), familial FTDP-17 syndromes, Parkinson's disease, and Huntington disease.